XLRN - Acceleron Pharma Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue13,99113,48127,77118,097
Cost of Revenue31,15026,00819,72021,901
Gross Profit-17,159-12,5278,051-3,804
Operating Expenses
Research Development72,75263,71845,06033,103
Selling General and Administrative34,50333,73829,09723,972
Non Recurring----
Others----
Total Operating Expenses138,405123,46493,87778,976
Operating Income or Loss-124,414-109,983-66,106-60,879
Income from Continuing Operations
Total Other Income/Expenses Net5,5161,5619,116-3,015
Earnings Before Interest and Taxes-124,414-109,983-66,106-60,879
Interest Expense----
Income Before Tax-118,898-108,422-56,990-63,894
Income Tax Expense-273224-
Minority Interest----
Net Income From Continuing Ops-118,871-108,454-57,014-63,894
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-118,871-108,454-57,014-63,894
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-118,871-108,454-57,014-63,894